Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 11.55 NOK
Change Today +0.05 / 0.43%
Volume 47.7K
NAVA On Other Exchanges
As of 10:25 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

navamedic (NAVA) Snapshot

11.50 NOK
Previous Close
11.50 NOK
Day High
11.75 NOK
Day Low
11.20 NOK
52 Week High
08/22/14 - 15.40 NOK
52 Week Low
03/31/15 - 9.80 NOK
Market Cap
Average Volume 10 Days
0.16 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for NAVAMEDIC (NAVA)

Related News

No related news articles were found.

navamedic (NAVA) Related Businessweek News

No Related Businessweek News Found

navamedic (NAVA) Details

Navamedic ASA, a pharmaceutical company, in-licenses, buys, and markets pharmaceuticals and other health care products in Norway and internationally. Its product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices, and other health care products. The company also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, tyrosinemia, maple sirup urine disease, homocystinuria, methylmalonic acidemia, propionic acidemia, and glutaric aciduria type 1, as well as carbohydrate metabolism, fat metabolism, and renal diseases. In addition, it sells consumer care products, including non-prescription pharmaceuticals primarily through pharmacies and/or drugstores. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Lysaker, Norway.

Founded in 2002

navamedic (NAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

navamedic (NAVA) Key Developments

Navamedic ASA Appoints Tom Rönnlund as New Ceo, Effective May 18, 2015

Tom Rönnlund has been appointed new CEO of Navamedic ASA. Tom Rönnlund joins the company from IMS Health Inc., where he held the position of General Manager for the Nordic & Baltic Region. Tom Rönnlund assumes his new responsibilities at the company on 18 May 2015.

Navamedic Eyes Acquisitions

Navamedic ASA (OB:NAVA) is looking for acquisition opportunities. Tom Ronnlund has been appointed new Chief Executive Officer of Navamedic ASA. "I am very excited to join Navamedic and am looking forward to build on the great work by the current management team in focusing the product portfolio for continued growth and improved profitability as well as actively pursue portfolio expansion through partnerships and potential acquisitions" says Tom Ronnlund.

Navamedic ASA Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Navamedic ASA reported earnings results for the fourth quarter and year ended December 31, 2014. The company had sales of NOK 61.9 million in the fourth quarter, a 47% increase from NOK 42.9 million in the corresponding quarter the previous year. The company's EBITDA for the quarter was NOK 4.0 million, compared to NOK 2.6 million the previous year. Earnings before taxes was NOK 0.4 million, against loss before taxes of NOK 0.9 million in 2013. The company reported operating results of NOK 1.6 million compared to NOK 1.3 million and net loss of NOK 0.6 million compared to NOK 1.2 million for the last year. Net cash flow from operations was NOK 0.4 million compared to net cash out flow from operations NOK 1.0 million for the last year. For the full year, 2014 sales ended at NOK 223.1 million, a 47% growth from NOK 151.8 million in 2013. The company's EBITDA grew by 71%, from NOK 7.7 million in 2013 to NOK 13.2 million last year. Earnings before taxes for 2014 came in at NOK 2.7 million, against loss before taxes of NOK 1.7 million in 2013. The company reported operating results of NOK 4.7 million compared to NOK 1.2 million and net loss of NOK 1.3 million compared to NOK 1.3 million for the last year. Net cash out flow from operations was NOK 10.8 million compared to NOK 15.7 million and purchase of intangible assets of NOK 0.8 million compared to NOK 2.3 million for the last year. The company expected 2015 a continued healthy EBITDA and EBITDA margin growth in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVA:NO 11.55 NOK +0.05

NAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NAVA.
View Industry Companies

Industry Analysis


Industry Average

Valuation NAVA Industry Range
Price/Earnings 72.6x
Price/Sales 0.4x
Price/Book 0.9x
Price/Cash Flow 9.6x
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVAMEDIC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at